Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H23NO7P2 |
Molecular Weight | 319.2289 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
InChI
InChIKey=MPBVHIBUJCELCL-UHFFFAOYSA-N
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
Molecular Formula | C9H23NO7P2 |
Molecular Weight | 319.2289 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/dosage/ibandronate.html
Sources: https://www.drugs.com/dosage/ibandronate.html
Ibandronic acid (INN) or ibandronate sodium (USAN) is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug. Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers. In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain.[4] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. Ibandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia, Ibandrix in Ecuador and Bondrova in Bangladesh.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP3104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16620148 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Boniva Approved UseUnknown |
|||
Primary | Boniva Approved UseUnknown |
|||
Primary | Boniva Approved UseDirections: Acne Clearing Cleanser Acne Clearing Tonic Acne Clearing Treatment 101 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
90.64 ng/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
IBANDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
549.24 ng × h/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
IBANDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32.38 h |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
IBANDRONIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 1 times / month multiple, oral Dose: 100 mg, 1 times / month Route: oral Route: multiple Dose: 100 mg, 1 times / month Sources: |
unhealthy, 55–74 years n = 183 Health Status: unhealthy Condition: osteoporosis Age Group: 55–74 years Sex: M+F Population Size: 183 Sources: |
|
2.5 mg 1 times / day multiple, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Sources: Page: p. 24 |
unhealthy, adult n = 465 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 465 Sources: Page: p. 24 |
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (NOS) (4%) Sources: Page: p. 24Musculoskeletal disorder NOS (1%) |
2 mg 1 times / 2 months multiple, intravenous Dose: 2 mg, 1 times / 2 months Route: intravenous Route: multiple Dose: 2 mg, 1 times / 2 months Sources: Page: p. 24 |
unhealthy, adult n = 442 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 442 Sources: Page: p. 24 |
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (NOS) (4%) Sources: Page: p. 24Musculoskeletal disorder NOS (2%) |
3 mg 1 times / 3 months multiple, intravenous Dose: 3 mg, 1 times / 3 months Route: intravenous Route: multiple Dose: 3 mg, 1 times / 3 months Sources: Page: p. 24 |
unhealthy, adult n = 458 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 458 Sources: Page: p. 24 |
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (NOS) (4%) Sources: Page: p. 24Musculoskeletal disorder NOS (2%) |
150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Other AEs: Agranulocytosis, Acute pancreatitis... Other AEs: Agranulocytosis (serious, 1 patient) Sources: Acute pancreatitis (serious, 1 patient) Acute pyelonephritis (serious, 1 patient) Sepsis (serious, 1 patient) Concussion (serious, 1 patient) Poisoning (serious, 1 patient) Follicle centre lymphoma diffuse small cell lymphoma (serious, 1 patient) Malignant tongue neoplasm (serious, 1 patient) Transient ischaemic attack (serious, 1 patient) Pulmonary embolism (serious, 1 patient) Deep vein thrombosis (serious, 2 patients) Influenza (below serious, 4 patients) Arthralgia (below serious, 8 patients) Rheumatoid arthritis (below serious, 4 patients) |
150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Other AEs: Death, Syncope... Other AEs: Death (serious, 1 patient) Sources: Syncope (serious, 2 patients) Pneumonia (serious, 1 patient) Retinal detachment (serious, 1 patient) Rectal haemorrhage (serious, 1 patient) Pneumoconiosis (serious, 1 patient) Nasopharyngitis (below serious, 7 patients) Nausea (below serious, 4 patients) Upper respiratory tract infection (below serious, 3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Musculoskeletal disorder NOS | 1% Disc. AE |
2.5 mg 1 times / day multiple, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Sources: Page: p. 24 |
unhealthy, adult n = 465 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 465 Sources: Page: p. 24 |
Gastrointestinal disorder (NOS) | 4% Disc. AE |
2.5 mg 1 times / day multiple, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Sources: Page: p. 24 |
unhealthy, adult n = 465 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 465 Sources: Page: p. 24 |
Musculoskeletal disorder NOS | 2% Disc. AE |
2 mg 1 times / 2 months multiple, intravenous Dose: 2 mg, 1 times / 2 months Route: intravenous Route: multiple Dose: 2 mg, 1 times / 2 months Sources: Page: p. 24 |
unhealthy, adult n = 442 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 442 Sources: Page: p. 24 |
Gastrointestinal disorder (NOS) | 4% Disc. AE |
2 mg 1 times / 2 months multiple, intravenous Dose: 2 mg, 1 times / 2 months Route: intravenous Route: multiple Dose: 2 mg, 1 times / 2 months Sources: Page: p. 24 |
unhealthy, adult n = 442 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 442 Sources: Page: p. 24 |
Musculoskeletal disorder NOS | 2% Disc. AE |
3 mg 1 times / 3 months multiple, intravenous Dose: 3 mg, 1 times / 3 months Route: intravenous Route: multiple Dose: 3 mg, 1 times / 3 months Sources: Page: p. 24 |
unhealthy, adult n = 458 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 458 Sources: Page: p. 24 |
Gastrointestinal disorder (NOS) | 4% Disc. AE |
3 mg 1 times / 3 months multiple, intravenous Dose: 3 mg, 1 times / 3 months Route: intravenous Route: multiple Dose: 3 mg, 1 times / 3 months Sources: Page: p. 24 |
unhealthy, adult n = 458 Health Status: unhealthy Condition: postmenopausal osteoporosis Age Group: adult Sex: F Population Size: 458 Sources: Page: p. 24 |
Influenza | below serious, 4 patients | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Rheumatoid arthritis | below serious, 4 patients | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Arthralgia | below serious, 8 patients | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Acute pancreatitis | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Acute pyelonephritis | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Agranulocytosis | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Concussion | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Follicle centre lymphoma diffuse small cell lymphoma | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Malignant tongue neoplasm | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Poisoning | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Pulmonary embolism | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Sepsis | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Transient ischaemic attack | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Deep vein thrombosis | serious, 2 patients | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 70 Health Status: unhealthy Condition: Osteoporosis Sex: F Population Size: 70 Sources: |
Upper respiratory tract infection | below serious, 3 patients | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Nausea | below serious, 4 patients | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Nasopharyngitis | below serious, 7 patients | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Death | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Pneumoconiosis | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Pneumonia | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Rectal haemorrhage | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Retinal detachment | serious, 1 patient | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Syncope | serious, 2 patients | 150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Osteoporosis Sex: M Population Size: 86 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0 |
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_pharmr_P1.pdf#page=4 Page: 4.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Dosing regimens and main adverse events of bisphosphonates. | 2001 Aug |
|
Effect of ibandronate on bone loss and renal function after kidney transplantation. | 2001 Jul |
|
Ibandronate in the treatment of prostate cancer associated painful osseous metastases. | 2002 |
|
Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? | 2002 Apr 22 |
|
Treatment of hypercalcemia of malignancy with bisphosphonates. | 2002 Dec |
|
Bisphosphonates for prevention of postmenopausal osteoporosis. | 2002 Feb |
|
Bisphosphonates for cancer patients: why, how, and when? | 2002 Jul |
|
Novel therapeutic options for osteoporosis. | 2002 Jul |
|
Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. | 2002 Jul |
|
The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. | 2002 May 6 |
|
Drugs in development: bisphosphonates and metalloproteinase inhibitors. | 2003 |
|
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. | 2003 Apr |
|
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years. | 2003 Aug |
|
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. | 2003 Aug |
|
Is ibandronate effective in multiple myeloma? | 2003 Dec |
|
[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium]. | 2003 Dec |
|
Injectable drug dampens bone loss. | 2003 Dec |
|
[How to treat tumor-induced hypercalcemia]. | 2003 Dec 15 |
|
Antitumor effects of bisphosphonates. | 2003 Feb 1 |
|
Mechanisms of osteolytic bone metastases in breast carcinoma. | 2003 Feb 1 |
|
Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. | 2003 Jan |
|
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. | 2003 Jul |
|
Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. | 2003 Jun |
|
Review of ibandronate in the treatment of osteoporosis. | 2003 Mar |
|
Effects of ibandronate on inflammation in mouse antigen-induced arthritis. | 2003 May |
|
Ibandronate: new options in the treatment of osteoporosis. | 2003 Nov |
|
Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples. | 2003 Nov 3 |
|
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. | 2003 Oct |
|
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. | 2004 Apr |
|
[Ibandronate]. | 2004 Feb |
|
Effect of augmentation cystoplasty on bone metabolism in chronic uremic rats. | 2004 Feb |
|
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. | 2004 Jan |
|
Hypercalcemia of malignancy. | 2004 Jan |
|
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. | 2004 Mar |
|
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. | 2004 Mar |
|
Nephrotoxicity of third-generation, intravenous bisphosphonates. | 2004 Mar 1 |
|
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. | 2004 Mar 22 |
|
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. | 2004 May |
|
Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. | 2004 May |
|
Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. | 2004 May |
|
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. | 2004 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/ibandronate.html
Oral: 150 mg orally once a month on the same day each month
IV Injection: 3 mg by IV injection over 15 to 30 seconds every three months.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25978957
Cells were cultivated in cell culture flasks at 37_Cand5%CO2. The culture media were as recommended by the American Type Culture Collection (ATCC) for MDA-MB-231 breast cancer DMEM (Sigma-Aldrich, St. Louis, MO, USA), which contained 10% fetal calf serum (FCS); PC-3 prostate carcinoma DMEM-F12 (Sigma-Aldrich) with 10% FCS. MG-63 and U2-OS osteosarcoma were cultured in AlphaMEM (Biochrom, Berlin, Germany) medium containing 10% FBS. For the HMC1.1 cell line, we used Iscove’s Modified Dulbecco’s Medium (IMDM; Thermo Fisher Scientific, Waltham, MA) supplemented with 260 nM thioglycerol (Sigma-Aldrich) and20%fetal bovine serum (FBS). All culture media contained 10 mg/mL gentamycin (Sigma-Aldrich). To guarantee optimal growth, cells were split two times a week and reseeded at a density of 2-5 x 105 cells/mL. One day after splitting, 32 mMsimvastatin (Sigma-Aldrich) or 150 mM ibandronate (Sigma-Aldrich) were added to the culture medium for 72 hours. This is the dose that attenuated cell proliferation with a half maximal effect. NADP/NADPH analyses were performed directly in 96-well culture plates after 24 or 48 hours
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:57:11 GMT 2023
by
admin
on
Sat Dec 16 15:57:11 GMT 2023
|
Record UNII |
UMD7G2653W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
BONDRONAT (AUTHORIZED: NEOPLASM METASTASIS)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
NCI_THESAURUS |
C67439
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IBANDRONIC ACID TEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
BONDENZA (WITHDRAWN: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
NCI_THESAURUS |
C443
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IBANDRONIC ACID TEVA (AUTHORIZED: FRACTURES, BONE)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IASIBON (AUTHORIZED: NEOPLASM METASTASIS)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
HALAVEN (AUTHORIZED: BREAST NEOLPLASMA)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IBANDRONIC ACID SANDOZ (AUTHORIZED: NEOPLASM METASTASIS)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IBANDRONIC ACID ACCORD (AUTHORIZED: WOUNDS AND INJURIES)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
NDF-RT |
N0000007707
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
WHO-VATC |
QM05BA06
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
BONVIVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IBANDRONIC ACID ACCORD (AUTHORIZED: NEOPLASTIC PROCESSES)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
DESTARA (WITHDRAWN: CANCER, HYPERCALCIMA)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IBANDRONIC ACID SANDOZ (AUTHORIZED: FRACTURES, BONE)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
WHO-ATC |
M05BA06
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
LIVERTOX |
494
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IBANDRONIC ACID TEVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IASIBON (AUTHORIZED: FRACTURES, BONE)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
XGEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
NDF-RT |
N0000175579
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
BONDRONAT (AUTHORIZED: FRACTURES, BONE)
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL997
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
DTXSID5048340
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
m6182
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
UMD7G2653W
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
115264
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
ALTERNATIVE | |||
|
3059
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
C65874
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
C073007
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
1404
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
IBANDRONIC ACID
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
722623
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
100000085439
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
SUB08092MIG
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
115265
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
DB00710
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
60852
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
7189
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
UMD7G2653W
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
114084-78-5
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY | |||
|
Ibandronate
Created by
admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
EXCRETED UNCHANGED |
The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% to 60% of the absorbed dose). Unabsorbed ibandronate is eliminated unchanged in the feces.
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
BINDING
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
DOSE |
|
||